Phase lb dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma

被引：0
|
作者：
Choueiri, Toni K. [1 ]
Plimack, Elizabeth R. [2 ]
Gupta, Shilpa [3 ]
Puzanov, Igor [4 ]
Mcdermott, David F. [5 ]
Tarazi, Jamal [6 ]
Keefe, Stephen [7 ]
Rosbrook, Brad [6 ]
Atkins, Michael B. [8 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Pfizer Oncol, San Diego, CA USA
[7] Merck Res Labs, N Wales, PA USA
[8] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
BJU INTERNATIONAL | 2015年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [1] Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naive patients with advanced renal cell carcinoma
    Larkin, J.
    Rini, B. I.
    Nathan, P.
    Thistlethwaite, F.
    Gordon, M.
    Martgnoni, M.
    Magazzu, D.
    Chiruzzi, C.
    Di Pietro, A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC)
    Choueiri, T. K.
    Plimack, E. R.
    Gupta, S.
    Cho, D.
    Hutson, T. E.
    Puzanov, I.
    George, S.
    Olencki, T.
    Vaishampayan, U.
    Chakrabarti, D.
    Pithavala, Y. K.
    Williams, J. A.
    Rosbrook, B.
    Tarazi, J. C.
    Atkins, M. B.
    BJU INTERNATIONAL, 2014, 114 : 4 - 5
  • [3] Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 693 - 703
  • [4] Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
    Rini, Brian I.
    Powles, Thomas
    Chen, Mei
    Puhlmann, Markus
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    FUTURE ONCOLOGY, 2021, 17 (03) : 241 - 254
  • [6] Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
    Mollica, Veronica
    Di Nunno, Vincenzo
    Massari, Francesco
    CHINESE CLINICAL ONCOLOGY, 2019, 8
  • [7] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    Szczylik, Cezary
    Markus, Maurice
    McDermott, Raymond S.
    Bedke, Jens
    Tartas, Sophie
    Chang, Yen-Hwa
    Tamada, Satoshi
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
  • [8] Initial clinical experience of pembrolizumab plus axitinib for advanced renal cell carcinoma
    Ieda, Takeshi
    Anno, Yuta
    Kurosawa, Makoto
    Kure, Akimasa
    Koyasu, Hiroki
    Takahata, Sohei
    Hino, Amiko
    Kitamura, Kosuke
    Nagata, Masayoshi
    Wakumoto, Yoshiaki
    Sakamoto, Yoshiro
    Tsujimura, Akira
    Horie, Shigeo
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 6 - 7
  • [9] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [10] Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma Comment
    Procopio, Giuseppe
    Nichetti, Federico
    Verzoni, Elena
    LANCET ONCOLOGY, 2020, 21 (12): : 1538 - 1539
12345